Skip to Content

Enoxaparin Injection

Last Updated: March 16, 2011
Status: Resolved

Products Affected - Description

Lovenox Injection, Sanofi-Aventis

Reason for the Shortage

Sanofi-Aventis had Lovenox on shortage due to current demand exceeding supply.

Estimated Resupply Dates

  • Sanofi-Aventis has available all Lovenox presentations including the 30 mg/0.3 mL (NDC 00075-0624-30), 40 mg/0.4 mL (NDC 00075-0620-40), 60 mg/0.6 mL (NDC 00075-0621-60), 80 mg /0.8 mL (NDC 00075-0622-80), 150 mg/1 mL (NDC 00075-2915-01), 120 mg/0.8 mL (NDC 00075-2912-01), 30 mg/0.3 mL Novaplus (NDC 00075-0624-31), 40 mg/0.4 mL Novaplus (NDC 00075-0620-41), 60 mg/0.6 mL Novaplus (NDC 00075-0621-61), 80 mg/0.8 mL Novaplus (NDC 00075-0622-81), 100 mg/1 mL Novaplus (NDC 00075-0623-01), 120 mg/0.8 mL Novaplus (NDC 00075-2912-02), and 150 mg Novaplus (NDC 00075-2915-02) syringes. The company also has available 300 mg multi-dose vials (NDC 00075-0626-03) and 300 mg multi-dose Novaplus vials (NDC 00075-0626-04). 
  • Sandoz has available enoxaparin 30 mg/0.3 mL (NDC 00781-3119-63), 40 mg/0.4 mL (NDC 00781-3119-64), 60 mg/0.6 mL (NDC 00781-3119-66), 80 mg/0.8 mL (NDC 00781-3119-68), 100 mg/1 mL (NDC 00781-3119-69), 120 mg/0.8 mL (NDC 00781-3121-68), and 150 mg/1 mL (NDC 00781-3121-69) syringes.

Related Shortages

Updated

March 16, 2011; February 16, 2011; February 7, 2011; January 20, 2011, University of Utah, Drug Information Service. Copyright 2011, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide